8-K: Cannabist Company Completes Major Debt Restructuring and Equity Issuance to Fortify Financial Position

The Cannabist Company Holdings Inc. has successfully completed a court-approved plan of arrangement, significantly restructuring its debt by exchanging existing notes for new senior and convertible notes, and issuing new common shares and anti-dilutive warrants.

Summary

• The Cannabist Company Holdings Inc. (Cannabist) completed a court-approved plan of arrangement on May 29, 2025, involving the exchange of existing senior secured notes for new debt and equity.
• Old notes, including $74,500,000 aggregate principal of 6.0% Senior Secured Convertible Notes due June 29, 2025, $185,000,000 aggregate principal of 9.5% Senior Secured Notes due February 3, 2026, and $25,750,000 aggregate principal of 9.0% Senior Secured Convertible Notes due March 19, 2027, were exchanged.
• New Senior Notes of up to $250,750,000 aggregate principal amount, bearing 9.25% cash interest, due December 31, 2028, were issued in exchange for the 2025 Convertible Notes, 2026 Notes, and $6,250,000 of the 2027 Convertible Notes.
• New Convertible Notes of up to $19,200,000 aggregate principal amount, bearing 9.0% cash interest, due December 31, 2028, were issued in exchange for $19,200,000 of the 2027 Convertible Notes.
• Both New Senior Notes and New Convertible Notes have maturity dates extendable to June 30, 2029, and subsequently to December 31, 2029, upon 30 days' notice and payment of a 0.50% extension fee on the aggregate principal amount.
• An aggregate of 118,209,105 new common shares (New CBST Common Shares) were issued to noteholders on a pro rata basis.
• An aggregate of 118,246,947 common share purchase warrants (Anti-Dilutive Warrants) were issued to existing Company shareholders of record as of May 27, 2025, on a pro rata basis, with an exercise price of C$0.14 per share and an expiry date of May 29, 2027.
• The company did not receive any consideration for the issuance of the Anti-Dilutive Warrants.
• The A&R Indenture includes new financial covenants: a minimum liquidity requirement of $15,000,000 in controlled accounts (commencing September 30, 2025) and a Consolidated Net Leverage Ratio target decreasing from 5.58x (March 31, 2026) to 3.44x (December 31, 2027 and thereafter).
• The first $36,500,000 of net proceeds from Approved Sales completed on or before March 31, 2026, may be used for general corporate purposes (Retained Proceeds).
• Net proceeds from Asset Sales in excess of Retained Proceeds or from other Asset Sales are subject to approval by a majority of independent directors for reinvestment or mandatory repayment of New Notes, with a 274-day period for open market purchases before par redemption.
• 40% of net proceeds from the exercise of Anti-Dilutive Warrants will be used for open market purchases of 2028 Notes and/or 2028 Convertible Notes.
• Supporting Senior Noteholders have the right to nominate two directors to Cannabist's Board of Directors, subject to certain conditions and regulatory approvals.
• The Board of Directors will be reduced to seven members after the 2025 annual and general meeting of shareholders, including the two Supporting Senior Noteholders Nominees.
• A third-party financial advisor (BRG) will be retained at Cannabist's expense to review financial reporting materials from March 31, 2026, onwards.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive because the company successfully completed a critical debt restructuring, which addresses immediate financial pressures and provides a clearer path forward. While there's dilution and new covenants, the avoidance of a more severe outcome and the extension of maturities are favorable. The anti-dilutive warrants also show consideration for existing shareholders.

Positives

• Successful completion of a complex, court-approved plan of arrangement, addressing significant outstanding debt obligations.
• Extension of maturity dates for a substantial portion of the company's debt (New Senior Notes and New Convertible Notes) from 2025-2027 to December 31, 2028, with options for further extensions to June 30, 2029, and December 31, 2029, providing greater financial flexibility.
• Issuance of anti-dilutive warrants to existing shareholders aims to mitigate the dilutive effect of the new common shares issued to noteholders.
• The initial $36,500,000 in net proceeds from Approved Sales can be used for general corporate purposes, offering immediate liquidity and operational flexibility.
• The inclusion of Supporting Senior Noteholders' nominees on the Board of Directors may foster better alignment of interests between debt and equity holders and enhance corporate governance.
• Retention of a financial advisor to review reporting materials provides increased transparency and oversight for noteholders.

Negatives

• Significant dilution of existing shareholders due to the issuance of 118,209,105 new common shares to noteholders as part of the debt exchange.
• The company is subject to new financial covenants, including minimum liquidity requirements ($15,000,000 from September 30, 2025) and a Consolidated Net Leverage Ratio that must decrease over time (from 5.58x on March 31, 2026, to 3.44x on December 31, 2027, and thereafter), which could trigger a default if not met.
• The requirement to use 40% of warrant exercise proceeds for open market purchases of new notes may limit the company's ability to use these funds for other growth initiatives or general working capital.
• The need for a court-approved plan of arrangement indicates prior financial distress or significant challenges in managing existing debt obligations.

Risks

• Failure to meet the new financial covenants, including the minimum liquidity requirement of $15,000,000 and the Consolidated Net Leverage Ratio targets, could trigger an Event of Default.
• The company operates in the cannabis industry, which is subject to complex and evolving state and local regulations, as well as federal illegality in the U.S., posing ongoing operational and legal risks.
• The ability to extend the maturity dates of the New Notes is at the Issuer's sole discretion and requires a 0.50% extension fee, which could add to debt service costs.
• The company's ability to generate sufficient net proceeds from Asset Sales to meet potential mandatory repurchase obligations for the New Notes is subject to market conditions and asset valuations.
• The beneficial ownership limitation on the conversion of New Convertible Notes (4.99%, extendable to 9.99%) could restrict certain holders' ability to fully convert their notes into common shares.
• Potential for future litigation or regulatory matters, as indicated by the detailed legal proceedings and compliance sections in the indenture.

Future Outlook

The restructuring provides Cannabist with a revised capital structure, extending debt maturities and establishing new financial covenants. The company aims to improve its financial health and operational stability through these changes, including maintaining minimum liquidity and adhering to a decreasing net leverage ratio. Future asset sales and warrant exercises are expected to contribute to debt management and working capital, with specific allocations for proceeds from Verano Common Shares sales.

Industry Context

The Cannabist Company Holdings Inc. operates in the highly regulated and evolving cannabis industry. The detailed provisions regarding 'Material Permits' and 'state or local cannabis regulatory approvals' underscore the unique compliance challenges and operational complexities inherent in this sector. The restructuring itself reflects a broader trend in the cannabis industry where companies are seeking to optimize capital structures and manage debt in a challenging regulatory and capital market environment.

Comparison to Industry Standards

• NA The document is a legal filing detailing a specific corporate restructuring and does not provide comparative financial or operational data against industry peers or benchmarks. Therefore, a specific assessment against global benchmarks or comparable companies/projects cannot be made based solely on the provided content.

Management Changes

Corporate Governance

Legal Proceedings

• The entire restructuring was completed pursuant to a court-approved plan of arrangement under Section 192 of the Canada Business Corporations Act (CBCA Proceedings), indicating a formal legal process to address the company's financial obligations.

Related Party Transactions

• Transactions with Affiliates (Affiliate Transactions) are subject to specific covenants: aggregate consideration over $5,000,000 requires terms no less favorable than arms-length; over $10,000,000 requires Board Resolution and disinterested director approval; over $25,000,000 requires a third-party appraisal approved by disinterested directors.

Stakeholder Impact

• Shareholders: Experience significant dilution from the issuance of 118,209,105 new common shares to noteholders. However, they received 118,246,947 anti-dilutive warrants, which offer a future opportunity to mitigate some of this dilution upon exercise.
• Noteholders (Old): Their existing notes were exchanged for new senior and convertible notes, extending maturities and providing a restructured debt instrument, potentially improving the recovery prospects of their investment.
• Noteholders (New / Supporting Senior Noteholders): Benefit from new senior secured notes with extended maturities, a 0.50% extension fee option, and enhanced corporate governance rights, including the ability to nominate directors and have a financial advisor review company reports. They also receive additional early consent consideration.
• Creditors: The restructuring aims to stabilize the company's financial position, which could improve the overall credit quality and repayment prospects for other creditors.
• Employees: The restructuring aims to ensure the company's continued operation, which is generally positive for employee job security, though no specific employee-related impacts are detailed beyond the Management Incentive Plan.

Next Steps

• Cannabist must maintain minimum liquidity of $15,000,000 in controlled accounts starting September 30, 2025.
• Cannabist must adhere to the Consolidated Net Leverage Ratio targets, which decrease quarterly from 5.58x (March 31, 2026) to 3.44x (December 31, 2027 and thereafter).
• Cannabist will retain a third-party financial advisor (BRG) from March 31, 2026, to review financial reporting.
• The Board of Directors will be reduced to seven members after the 2025 annual and general meeting of shareholders.
• Cannabist may elect to extend the maturity dates of the New Senior Notes and New Convertible Notes to June 30, 2029, and then to December 31, 2029, by providing 30 days' notice and paying a 0.50% extension fee.
• The company will apply 40% of net proceeds from warrant exercises to open market purchases of 2028 Notes and/or 2028 Convertible Notes.
• The company will continue to seek to obtain Waivers of Priority for its leased premises to meet the Security Coverage Test.

Key Dates

Recommendation

Keywords

Debt Restructuring, SEC Filing, Senior Secured Notes, Convertible Notes, Warrants, Equity Issuance, Financial Covenants, Liquidity, Leverage Ratio, Asset Sales, Corporate Governance, Cannabis Industry, SEC, Trust Indenture, CBCA Proceedings